ReWalk Robotics Ltd. - RWLK STOCK NEWS

ReWalk Robotics Ltd. (Nasdaq:RWLK) has fully repaid its $20 million credit line with Kreos Capital, which was established in 2015. This move eliminates all outstanding obligations to Kreos as of December 29, 2020. The initial drawdown was $12 million in 2016, followed by an additional $8 million.

ReWalk develops wearable robotic exoskeletons aimed at enhancing the lives of individuals with lower limb disabilities. The company's commitment focuses on innovative technologies to improve quality of life.

ReWalk Robotics, Ltd. (Nasdaq: RWLK) announced a donation of its ReStore Exo-suit to Brooks Rehabilitation in Jacksonville, Florida, to support stroke recovery. The device will enhance gait training for patients in specialized Neuro Recovery Centers. CEO Larry Jasinski emphasized the importance of robotic devices during the COVID-19 pandemic, highlighting their role in maintaining health safety protocols. Brooks Rehabilitation, a leader in physical therapy, will utilize the exo-suit to improve rehabilitation outcomes for stroke patients.

ReWalk Robotics has secured its first supply contract with a private German health insurer, enabling eligible spinal cord injury (SCI) beneficiaries to procure the ReWalk 6.0 exoskeleton system. This agreement follows earlier contracts with several statutory insurers in Germany, marking significant progress in the adoption of robotic technology for rehabilitation. CEO Larry Jasinski emphasized the impact of this contract on enhancing care standards for individuals with SCIs. The ReWalk 6.0 was added to Germany's Medical Device Directory in 2018, facilitating further contracts with insurers.

ReWalk Robotics Ltd. (RWLK) announced the closing of a private placement, raising approximately $8 million by issuing 5,579,776 shares and warrants. The shares were priced at $1.43375 each, with warrants exercisable at $1.34. H.C. Wainwright & Co. acted as the placement agent. Proceeds will support marketing efforts for the ReStore device and R&D activities. The company is required to file a registration statement with the SEC by December 18, 2020, to facilitate the resale of these securities.

ReWalk Robotics Ltd. (RWLK) announced a private placement to raise $8.0 million by issuing 5,579,776 ordinary shares and warrants for $1.43375 per share, with warrants exercisable at $1.34. The funds will support marketing and sales efforts for the ReStore device, R&D activities, and general corporate needs. The closing is expected around December 7, 2020. The company must file a registration statement with the SEC within 15 days for the resale of shares from this transaction.

ReWalk Robotics Ltd. (RWLK) reported its Q3 2020 financial results with total revenue of $0.7 million, down from $1.2 million in Q3 2019. The decline is attributed to fewer units sold due to limited market access amid COVID-19. The company received Medicare Provider certification from CMS and secured an additional contract with a German payor. Operating expenses decreased to $3.5 million, and the net loss slightly improved to $3.3 million. As of September 30, 2020, ReWalk had $18.1 million in cash and $3.4 million in debt, indicating a solid liquidity position for ongoing operations.

ReWalk Robotics Ltd. (Nasdaq: RWLK) announced its participation in the H.C. Wainwright virtual conference on November 12, 2020, at 1:30 PM EST. Key executives, including CEO Larry Jasinski, CFO Ori Gon, and VP of Marketing Andy Dolan, will present a fireside chat. The presentation can be accessed via the company's website or the provided link. ReWalk specializes in developing wearable robotic exoskeletons aimed at improving the quality of life for individuals with lower limb disabilities.

ReWalk Robotics Ltd. (Nasdaq: RWLK) announced its third quarter 2020 financial results release on November 10, 2020, before U.S. market opening. CEO Larry Jasinski and CFO Ori Gon will host a conference call at 8:30 A.M. EST to discuss the results. Investors can join via toll-free and international numbers or access the live webcast.

ReWalk develops wearable robotic exoskeletons aimed at improving the quality of life for individuals with lower limb disabilities due to spinal cord injuries or strokes, with operations in the U.S., Israel, and Germany.

ReWalk Robotics, Ltd. (RWLK) received Medicare Provider certification from the Centers for Medicare & Medicaid Services, allowing direct billing for its Personal Exoskeleton. This certification is effective in most U.S. states, following the issuance of the HCPCS Level II Code K1007 for the ReWalk 6.0 Exoskeleton system, effective October 1, 2020. CEO Larry Jasinski highlighted the importance of this step for improving access to their technology. The company aims to pursue in-network status with private insurers to further enhance access for users.